Rocket Pharmaceuticals (RCKT) Payables (2016 - 2025)
Historic Payables for Rocket Pharmaceuticals (RCKT) over the last 10 years, with Q3 2025 value amounting to $28.3 million.
- Rocket Pharmaceuticals' Payables fell 2390.06% to $28.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $28.3 million, marking a year-over-year decrease of 2390.06%. This contributed to the annual value of $37.8 million for FY2024, which is 1738.85% down from last year.
- According to the latest figures from Q3 2025, Rocket Pharmaceuticals' Payables is $28.3 million, which was down 2390.06% from $40.5 million recorded in Q2 2025.
- In the past 5 years, Rocket Pharmaceuticals' Payables ranged from a high of $45.8 million in Q4 2023 and a low of $19.6 million during Q4 2021
- For the 5-year period, Rocket Pharmaceuticals' Payables averaged around $30.9 million, with its median value being $30.6 million (2023).
- Per our database at Business Quant, Rocket Pharmaceuticals' Payables surged by 10274.19% in 2021 and then tumbled by 4749.96% in 2022.
- Rocket Pharmaceuticals' Payables (Quarter) stood at $19.6 million in 2021, then skyrocketed by 86.9% to $36.7 million in 2022, then rose by 24.9% to $45.8 million in 2023, then fell by 17.39% to $37.8 million in 2024, then fell by 25.3% to $28.3 million in 2025.
- Its last three reported values are $28.3 million in Q3 2025, $40.5 million for Q2 2025, and $32.4 million during Q1 2025.